Gurrieri et al 1 recently described a familial case with mild BeckwithWiedemann Syndrome (BWS) and mild Silver-Russell Syndrome (SRS) phenotypes due to opposite parental origin of a 198 kb deletion on chromosome 11p15.5. Our group identified another deletion (of 60 kb) that eliminates a subfragment of the region missing in the 198 kb deletion on the paternal chromosome, but is associated with severe Intra-Uterine Growth Restriction (IUGR). 2 Careful analysis of the epigenetic marks reported by the ENCODE Project for this genomic region provides insights into the location of the cis-acting regulatory elements of the 11p15.5 region and a possible explanation for the phenotypic differences between the two clinical cases.
Altered expression of imprinted genes on chromosome 11p15.5 is associated with the growth disorders BWS (MIM #130650) and SRS (MIM #180860). 3 The 11p15.5 imprinted gene cluster is divided into two distinct domains, each including an own imprinting control region (ICR). BWS and SRS are characterized by opposite growth phenotypes, and DNA methylation defects in the ICRs account for 60% of their molecular abnormalities. However, in a significant number of patients (430%) no molecular defect has been identified yet.
The centromeric domain of the cluster is 800 kb long and includes several imprinted genes. Its ICR (ICR2) is located within KCNQ1 intron 10, it is methylated on the maternal chromosome and encompasses the promoter for the non-coding RNA KCNQ1OT1 (antisense to KCNQ1). Transcription of KCNQ1OT1 on the non-methylated paternal chromosome results in cis bi-directional silencing of the flanking imprinted genes. Among these genes, there is CDKN1C that encodes a cyclin-dependent kinase inhibitor and has growth suppressing properties. Decreased CDKN1C activity due to the loss of ICR2 methylation and maternal KCNQ1OT1 activation has been associated with BWS, 4 whereas increased CDKN1C activity due to maternal 11p15.5 duplication has been involved in SRS. 5 John et al's 6 work in the mouse indicates that, in addition to ICR2, Cdkn1c is regulated by distant enhancers likely located within the Kcnq1 gene. Enhancer sequences are identified as conserved non-coding regions (4100 bp, which are 470% identical between human and rodents) that are enriched in specific histone modifications (ie, H3K27acetylation, H3K4monomethylation), DNase hypersensitive sites and transcription factor binding. 7, 8 Based on the conservation between human, mouse and rat genomes 9 and the epigenetic marks deposited by the ENCODE project, 8 we found three sequences meeting the features of enhancers within the KCNQ1 gene region (Figure 1, green boxes and Supplementary Figure 1) . Two of these sequences are located within KCNQ1 last intron (regions 1 and 2) and one in intron 1 immediately 3 0 to the exon 1 boundary (region 3). Some of the characteristic features of the enhancers are also present in the ICR2/KCNQ1OT1 promoter which, however, also displays H3K4Me3 marks (not shown).
In human, rare chromosome imbalances involving ICR2 and different portions of the KCNQ1 gene have been reported associated with BWS/SRS phenotypes and severe IUGR (Figure 1) . A deletion of 255-387 kb removing most of KCNQ1 (from intron 1b to intron 14) was first described. 10, 11 This deletion results in CDKN1C downregulation and BWS when maternally inherited, but in normal phenotype on paternal transmission. More recently, a 198 kb deletion extending from KCNQ1 intron 9 to exon 15 was found associated with mild BWS when maternally inherited and mild SRS when paternally inherited. 1 Finally, a paternal deletion of 60 kb resulting in KCNQ1OT1 silencing and CDKN1C activation was associated with severe and recurrent IUGR. 2 The existence of multiple CDKN1C enhancers was originally proposed to explain the phenotypes of the 255-387 kb and 198 kb deletions. 1, 11 To reconcile the phenotypes of all three deletions, we now propose that these enhancers are all (or mostly) located within the 255-387 kb deletion, in part within the 198 kb deletion, but none within the 60 kb deletion (Figure 1) . So, by eliminating ICR2 but keeping the enhancers on the paternal chromosome, the 60 kb deletion would abolish the silencing effect of the KCNQ1OT1 RNA and lead to CDKN1C activation and severe growth restriction. In contrast, by eliminating one or more enhancers, the larger deletions would result in weaker (198 kb deletion) or no activation (255-387 kb deletion) of the paternal CDKN1C. Interestingly, all the candidate enhancer sequences indicated by the ENCODE data lie outside the 60 kb deletion and likely within the 255-387 kb deletion, but only two of them are within the 198 kb deletion, thus meeting the characteristics proposed for the CDKN1C enhancers. These regions may also be involved in imprinting control, as they are included in two maternal duplications ( Figure 1 ) associated with ICR2 hypomethylation and BWS. 12, 13 Intriguingly, region 3 also harbors strong binding sites for CTCF (Supplementary Figure 1) , which have been shown to interact with other CTCF binding sequences near CDKN1C, possibly forming higher-order chromatin structures or insulators that may be disrupted by the duplication and result in ICR2 imprinting alteration. 14 In conclusion, by integrating information on chromosome rearrangements and chromatin features, we have identified three sequences meeting the features predicted for CDKN1C enhancers that help explain the phenotypes associated with different 11p15.5 deletions. Further experimental work in animal models (transgenic enhancer assays) and in the patients (mutation screening) will possibly confirm their functional role.
